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Abstract
Background: In the United Kingdom (UK), there is an extensive market for the class 'A' drug
heroin. Many heroin users spend time in prison. People addicted to heroin often require prescribed
medication when attempting to cease their drug use. The most commonly used detoxification
agents in UK prisons are buprenorphine, dihydrocodeine and methadone. However, national
guidelines do not state a detoxification drug of choice. Indeed, there is a paucity of research
evaluating the most effective treatment for opiate detoxification in prisons. This study seeks to
address the paucity by evaluating routinely used interventions amongst drug using prisoners within
UK prisons.
Methods/Design: The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) Prisons Pilot
Study will use randomised controlled trial methodology to compare the open use of buprenorphine
and dihydrocodeine for opiate detoxification, given in the context of routine care, within HMP
Leeds. Prisoners who are eligible and give informed consent will be entered into the trial. The
primary outcome measure will be abstinence status at five days post detoxification, as determined
by a urine test. Secondary outcomes during the detoxification and then at one, three and six
months post detoxification will be recorded.
Background
In the United Kingdom (U.K), there is an extensive market
for the sale of heroin, an illicit class 'A' drug. Precise fig-
ures of how many people use and are dependent on her-
oin are difficult to establish as there has never been a
national prevalence survey [1]. The link between crime
and illicit drug use, specifically heroin use, is well recog-
nised. In 2002, 63% of injecting drug users (IDUs) in con-
tact with specialist drugs services in England and Wales
reported having ever been in prison or a young offenders'
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heroin require medical help in reducing and stopping
their use due to the drug's highly addictive properties.
Neither the current evidence base [1] nor the national
guidelines on the clinical management of drug misuse [3]
stipulate a 'drug of choice' for rapid opiate detoxification.
In the absence of an established evidence base, a wide
variety of agents have therefore been used including meth-
adone, dihydrocodeine, buprenorphine, lofexidine and
clonidine. Historically within prisons, the most com-
monly used drug for opiate detoxification has been dihy-
drocodeine. Anecdotally this was because of a reluctance
to prescribe methadone following a small number of
methadone related deaths in the prison setting. Dihydroc-
odeine is attractive to clinicians as it has a shorter half-life
than methadone, and seems equally acceptable to users.
However, there has been a move away from prescribing
dihydrocodeine due to its potential for diversion by pris-
oners into the prison shadow economy. Increasingly,
buprenorphine is now being prescribed and recent policy
supports methadone prescribing [4]. Buprenorphine – in
the form of sub-lingual tablets – is relatively new for the
purpose of opiate detoxification in the UK, especially
within the prison estate. It has the potential advantage of
having a good safety profile, better retention in treatment
and lower withdrawal severity when compared to metha-
done, lofexidine or clonidine [5-8]. Her Majesty's Prison
(HMP) Leeds saw a 42% increase in buprenorphine pre-
scribing between April 2002 and January 2004. Buprenor-
phine is increasingly being prescribed in the community
[9].
There appears to be a paucity of clinical trials conducted
in the UK prison setting which have evaluated medication
for opiate detoxification. Whilst one study evaluated the
withdrawal severity of methadone and lofexidine [10], the
rates of completion were not sufficient to detect a statisti-
cally significant difference between the two medications.
One study has compared sublingual buprenorphine with
dihydrocodeine for postoperative pain, outside of the
prison setting [11]. In 2004, the Leeds Evaluation of Effi-
cacy of Detoxification Study (LEEDS) team conducted the
first randomised controlled trial (RCT) to compare
buprenorphine and dihydrocodeine for opiate detoxifica-
tion in the community [12]. The results have recently
been submitted for publication. The LEEDS trial has since
expanded to evaluate the open use of buprenorphine ver-
sus dihydrocodeine in the prison primary healthcare set-
ting.
Methods
Design
LEEDS is a pragmatic open label randomised controlled
trial.
Randomisation will be random block size, which will be
administered centrally in the Academic Department of
Psychiatry and Behavioural Sciences, University of Leeds.
Opaque consecutively numbered envelopes will be pre-
pared. If a prisoner is both eligible and agreeable the next
envelope will be opened and the intervention allocated.
Confounding variables i.e. doctor participant relation-
ships, drugs worker participant relationships will all be
controlled for by randomisation. Some confounding var-
iables cannot be randomised. These include the inherent
difference in the two detoxification programmes, i.e. the
daily supervised consumption of buprenorphine.
Setting and recruitment
The study will take place in prison primary healthcare at
HMP Leeds, West Yorkshire, England. HMP Leeds is a cat-
egory B local prison, which accepts all adult male prison-
ers aged 21 and over from West Yorkshire. Participants
will be recruited from the medical reception area on first
arrival into the prison, where prisoners are routinely
offered at detoxification regime.
LEEDS is intended to complement rather than compete
with research taking place in a community primary or sec-
ondary care setting. Much of the current evidence base for
pharmacological treatment of drug use comes from stud-
ies that have taken place in an inpatient or residential set-
ting. There is an urgent need to verify whether such
research is applicable to the prison primary healthcare
environment. The ethos of the study will be a collabora-
tive project between prison primary healthcare, primary
care and the secondary care academic departments and
service providers.
Sample size
Currently no randomised controlled trials relevant to
these comparisons have been undertaken in the prison
setting. However, from the results of our community
study comparing these agents we estimate that with a sam-
ple size of 120 we will have a finding of clinical and statis-
tical significance. Power calculations were undertaken
using Sample Power 1.20 developed by SPSS Inc., com-
paring two groups (60 individuals in each) and for α =
0.05 (two-sided). The power calculations are shown
below in Table 1.
Eligibility
Inclusion criteria
1. Male or female
2. 18 – 65 years old
3. Using illicit opiates as confirmed by a urine test taken
at first assessment.Page 2 of 5
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monitored process and remain abstinent from opiates.
5. Willing to give informed consent after receiving the par-
ticipant information booklet
6. Remaining in custody for longer than 28 days
Exclusion criteria
1. Contraindications to methadone or buprenorphine
2. Co-existing acute medical conditions requiring emer-
gency admission for hospital care so precluding detoxifi-
cation in the prison setting
3. Currently undergoing detoxification from other addic-
tive drugs whereby concurrent detoxification from opiates
would not be clinically indicated
4. Previously been randomised into this trial
Interventions
The treatment option will be concealed from both partic-
ipant and clinician at time of assessment. Both parties will
remain blind to the selected treatment option until the
envelope is opened.
1. Dihydrocodeine, given openly, in the context of the
standard prison doctor and drugs worker support.
2. Buprenorphine, given openly, in the context of the
standard prison doctor and drugs worker support.
The reducing regimen of both dihydrocodeine and
buprenorphine (over less than 16 days) will be at the dis-
cretion of the prescribing doctor. However, the dose
should not exceed this standard regime (Table 2 and Table
3).
Outcomes
Primary outcome
Abstinence from street opiates at five days post detox as
indicated by urine test. Should the person not finish the
course of detoxification or refuse to give urine then this
will be considered as a positive urine test for opiates.
Secondary outcomes
During the period of detoxification
Adverse events
Clinicians will record any details of adverse events in the
usual way i.e. an entry will be made in the participants'
records. Those adverse events clearly resulting in clinically
significant distress to study participants or of major con-
cern to clinicians will be recorded. The LEEDS trial co-
ordinator will extract data from clinical records, for the
period of detoxification, and transcribe these to a data-
base.
Leaving the study early
Perceived reasons for withdrawal will be recorded.
Inappropriate use of prescribed medication
Examples of this include intentional overdose and stor-
ing, trading, swapping or selling of prescribed medication.
Service related outcomes
Admission to hospital, Accident and Emergency and in
patient stays in prison healthcare will be recorded.
At one-month, three-month and six-month post detoxification
Abstinence status
Evidence of this taken from clinical notes if the participant
is still in HMP Leeds or has been transferred to another
prison. If the participant has been released into the com-
munity then they will be contacted via address or tele-
phone number given at point of randomisation, or by
accessing local community drugs service records.
Table 1: Power calculations for sample of 120Difference between groups
Power Difference between groups Power
70% × 60% 21% 40% × 30% 21%
70% × 50% 61% 40% × 20% 67%
70% × 45% 80% 40% × 15% 88%
70% × 40% 92%
60% × 50% 20% 30% × 20% 24%
60% × 40% 59% 30% × 15% 50%
60% × 35% 79% 30% × 10% 79%
60% × 30% 92%
50% × 40% 20% 20% × 15% 11%
50% × 30% 61% 20% × 10% 33%
50% × 25% 82% 20% × 5% 70%Page 3 of 5
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Contacts with hospitals and Accident and Emergency
departments will be noted. For those participants still in
the prison estate, use of inpatient prison healthcare will be
recorded.
The project team recognise the difficulty in tracking peo-
ple with drug problems who have subsequently been
released from prison across this period.
Data collection
The outside of the allocation envelope will be completed
by the prison doctor before opening. This will record Unit
number, date of birth and estimate of severity of addiction
and expected prognosis.
The LEEDS trial co-ordinator will collect details of drug of
allocation, background history, and use of opiates from
the participant's health records. The primary outcome and
data at one, three months and six months after randomi-
sation will again be collected by the LEEDS trial co-ordi-
nator. There will be minimal additional contact with the
participants. LEEDS is designed to avoid the complication
of the care provided to this group.
All data will be double entered into an EPI-INFO database
customised for the LEEDS project and the simple analysis
involved with this project will also be undertaken in that
package.
Analysis
After data entry, all analysis will be undertaken in Epi-
info. The analysis of the primary outcomes will be of a
simple 2 × 2 table (see Table 4, below). Dummy tables
have been constructed for all secondary outcomes. These
tables are designed to be rigid templates for the final write
up of the project, and to protect the researchers from bias,
once the data are disclosed. An example is given below,
but dummy tables for all data to be collected have been
constructed, a priori, for every variable to be collected.
Discussion
The information which the LEEDS project team aim to
gain from the trial is twofold. Firstly, once data collection
is complete, we hope to show either a statistically signifi-
cant difference between the efficacy of the two detoxifica-
tion agents or alternatively, that no statistically significant
difference exists. We expect that the results will influence
prison healthcare policy if the trial demonstrates one
detoxification agent is significantly more efficacious than
another. This may begin locally within HMP Leeds and
potentially influence prison prescribing policy nationally.
Information about the methodological practicalities of
conducting a randomised controlled trial in the prison
setting will be enormously valuable. The research team
have previously described the practicalities of conducting
a detoxification RCT in primary care [13]. Yet, to our
knowledge, only one British prison RCT comparing
detoxification agents exists [10]. Therefore, conducting
this current trial will provide a wealth of previously
unknown knowledge about the feasibility, practicality
and day to day groundwork and management involved in
running a trial in the prison environment. This informa-
tion may be important for future research teams, and will
also demonstrate that trials can be done within prisons.
Given the factors above, the importance of this study can-
not be under estimated. Guidelines for substance misuse
treatment in prison are not grounded on an established
evidence base as there is an extreme paucity of trials con-
Table 2: Buprenorphine detoxification
Day Dose (mg)
1 6
2 8
3 8
4 6
5 6
6 4
7 3.6
8 3.2
9 2.8
10 2.4
11 2.0
12 1.6
13 1.2
14 0.8
15 0.4
Table 3: Dihydrocodeine detoxification
Day Morning Evening
1 XXXX 2 × 120 mg
2 2 × 120 mg 2 × 120 mg
3 1 × 120 mg
1 × 90 mg
1 × 120 mg
1 × 90 mg
4 1 × 120 mg
1 × 90 mg
1 × 120 mg
1 × 90 mg
5 2 × 90 mg 2 × 90 mg
6 2 × 90 mg 2 × 90 mg
7 1 × 90 mg
1 × 60 mg
1 × 90 mg
1 × 60 mg
8 1 × 90 mg
1 × 60 mg
1 × 90 mg
1 × 60 mg
9 2 × 60 mg 2 × 60 mg
10 2 × 60 mg 2 × 60 mg
11 1 × 60 mg 2 × 60 mg
12 1 × 60 mg 2 × 60 mg
13 1 × 60 mg 1 × 60 mg
14 1 × 60 mg 1 × 60 mg
15 XXXX 1 × 60 mgPage 4 of 5
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envisage that this trial will provide invaluable data about
the efficacy of two routinely used detoxification agents
which have rarely been studied within the prison environ-
ment.
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